NEOS - ネオス・ファ―マシュ―ティカルズ (Neos Therapeutics Inc.) ネオス・ファ―マシュ―ティカルズ

 NEOSのチャート


 NEOSの企業情報

symbol NEOS
会社名 Neos Therapeutics Inc (ネオス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 ネオス・セラピューティクス(Neos Therapeutics Inc.)は製薬会社である。同社は修正薬物送達技術プラットフォームを利用して製品の開発、製造及び商品化に従事する。同社は医薬品の開発、製造、販売に従事する。同社は注意欠如・多動性障害(ADHD)の治療向け製品を開発するプラットフォームを利用する。製品候補は、患者にやさしい徐放性(XR)口腔内崩壊錠剤(ODT)または液体懸濁剤剤形の薬剤である。ブランド製品と製品候補はADHD、メチルフェニデートとアンフェタミンの治療のための2つ以上の処方医薬品を含む。修正放出薬物送達プラットフォームは徐放性ODTと液体懸濁液投与形態の薬物を作製することを可能にする。同社はAdzenys XR-ODT、Cotempla XR-ODT、NT-0201の開発に従事する。   ネオス・ファ―マシュ―ティカルズは米国の医薬品会社。主に薬剤送達技術を利用し、既に商品化されている製薬の改良、開発に従事する。薬剤候補に、注意欠陥多動障害(ADHD)治療薬で、患者の負担が軽い徐放性タイプの経口薬を開発する。また、ADHD治療薬のメチルフェニデ―トとアンフェタミンの両方を取り入れた製薬も開発する。本社はキサス州。   
本社所在地 2940 N. Hwy. 360 Grand Prairie TX 75050 USA
代表者氏名 Alan Heller アラン・ヘラー
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 972-408-1360
設立年月日 34639
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 138人
url www.neostx.com
nasdaq_url https://www.nasdaq.com/symbol/neos
adr_tso
EBITDA EBITDA(百万ドル) -48.18100
終値(lastsale) 4.18
時価総額(marketcap) 124036943.8
時価総額 時価総額(百万ドル) 118.99240
売上高 売上高(百万ドル) 36.57400
企業価値(EV) 企業価値(EV)(百万ドル) 150.86740
当期純利益 当期純利益(百万ドル) -60.12500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Neos Therapeutics Inc revenues increased from $10.8M to $22.1M. Net loss decreased 17% to $29.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and Development - Balancing v decrease of 26% to $3.9M (expense) Other Income net increase from $175K to $594K (income).

 NEOSのテクニカル分析


 NEOSのニュース

   Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference  2021/01/04 21:01:00 GlobeNewswire
DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company…
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Neos Therapeutics, Inc.  2020/12/10 21:52:00 PR Newswire
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. ("NEOS" or the "Company") (NASDAQ: NEOS) in connection with the proposed acquisition of the Company by…
   Thinking about buying stock in Neos Therapeutics, Oncternal Therapeutics, Heat Biologics, FuelCell Energy, or Cinedigm Corp?  2020/12/10 15:50:00 PR Newswire
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, ONCT, HTBX, FCEL, and CIDM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Neos Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Neos Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NEOS  2020/12/10 15:31:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Neos Therapeutics, Inc. (NASDAQ: NEOS) to Aytu BioScience, Inc. is fair to Neos shareholders. Upon the effectiveness of the merger, Neos stockholders are expected to receive 0.1088 shares of Aytu common stock for each share of Neos common stock held. Halper Sadeh encourages Neos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh
   Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company - Stocks News Feed  2020/12/10 11:38:34 Stocks News Feed
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’s product portfolio of best-in-class… Read More »Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Neos Therapeutics, Inc.  2020/12/10 21:52:00 PR Newswire
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. ("NEOS" or the "Company") (NASDAQ: NEOS) in connection with the proposed acquisition of the Company by…
   Thinking about buying stock in Neos Therapeutics, Oncternal Therapeutics, Heat Biologics, FuelCell Energy, or Cinedigm Corp?  2020/12/10 15:50:00 PR Newswire
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, ONCT, HTBX, FCEL, and CIDM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Neos Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Neos Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NEOS  2020/12/10 15:31:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Neos Therapeutics, Inc. (NASDAQ: NEOS) to Aytu BioScience, Inc. is fair to Neos shareholders. Upon the effectiveness of the merger, Neos stockholders are expected to receive 0.1088 shares of Aytu common stock for each share of Neos common stock held. Halper Sadeh encourages Neos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh
   Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company - Stocks News Feed  2020/12/10 11:38:34 Stocks News Feed
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’s product portfolio of best-in-class… Read More »Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company
   Neos Therapeutics to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020  2020/11/02 13:00:00 GlobeNewswire
DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company…
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Neos Therapeutics, Inc.  2020/12/10 21:52:00 PR Newswire
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Neos Therapeutics, Inc. ("NEOS" or the "Company") (NASDAQ: NEOS) in connection with the proposed acquisition of the Company by…
   Thinking about buying stock in Neos Therapeutics, Oncternal Therapeutics, Heat Biologics, FuelCell Energy, or Cinedigm Corp?  2020/12/10 15:50:00 PR Newswire
NEW YORK, Dec. 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEOS, ONCT, HTBX, FCEL, and CIDM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Neos Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Neos Therapeutics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – NEOS  2020/12/10 15:31:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Neos Therapeutics, Inc. (NASDAQ: NEOS) to Aytu BioScience, Inc. is fair to Neos shareholders. Upon the effectiveness of the merger, Neos stockholders are expected to receive 0.1088 shares of Aytu common stock for each share of Neos common stock held. Halper Sadeh encourages Neos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh
   Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company - Stocks News Feed  2020/12/10 11:38:34 Stocks News Feed
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s footprint in pediatrics and expanding its presence in adjacent specialty care segments Opportunity to leverage and further enhance Neos RxConnect, a best-in-class patient support program, for Aytu’s product portfolio of best-in-class… Read More »Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical Company
   Neos Therapeutics to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020  2020/11/02 13:00:00 GlobeNewswire
DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company…

 関連キーワード  (医薬品 米国株 ネオス・ファ―マシュ―ティカルズ NEOS Neos Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)